^
    Back
    Association details:
    Biomarker:ATF7IP-PDGFRB fusion
    Cancer:Acute Lymphocytic Leukemia
    Drug:dasatinib (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Blood
    Title:

    Acute Lymphoblastic Leukemia Patient with Variant ATF7IP/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report

    Excerpt:
    …our patient with a variant ATF7IP/PDGFRB fusion had a poor initial treatment response to chemotherapy but responded well to TKI-based therapy and is now doing well in continuous remission…. The patient is now receiving the Chinese Children’s Cancer Group (CCCG)-2015-ALL protocol plus dasatinib and remains free of molecularly detectable disease.
    DOI:
    10.12659/AJCR.906300